Precision Oncology: 2023 in Review-Reference-Cited by-同舟云学术

Precision Oncology: 2023 in Review

Published:2023-12-12 Issue:12 Volume:13 Page:2525-2531
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Murciano-Goroff Yonina R.¹,Suehnholz Sarah P.²³,Drilon Alexander¹⁴,Chakravarty Debyani²³

Affiliation:

1. 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

2. 2Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

3. 3Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

4. 4Weill Cornell Medical College, New York, New York.

Abstract

Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/13/12/2525/3391100/2525.pdf

Reference29 articles.

1. Precision oncology: 2022 in review;Rosen;Cancer Discov,2022

2. Single-agent Divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation;Sacher;N Engl J Med,2023

3. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer;Mohanty;Sci Adv,2023

4. A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors [abstract];Murciano-Goroff

5. Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor [abstract];Koltun

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular substratification of endometrial carcinomas with no special molecular profile (NSMP) by using a limited NGS custom panel may facilitate effective patient selection for the PIK3CA-targeted therapy;Virchows Archiv;2024-09-05

2. Identifications of Similarity Metrics for Patients With Cancer: Protocol for a Scoping Review;JMIR Research Protocols;2024-09-04

3. Transforming Health Care Landscapes: The Lever of Radiology Research and Innovation on Emerging Markets Poised for Aggressive Growth;Journal of the American College of Radiology;2024-08

4. NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis;Cancers;2024-04-19

5. Precision Immuno-Oncology in NSCLC through Gender Equity Lenses;Cancers;2024-04-04